Toronto, Canada (PRWEB) November 08, 2013
Despite the growing prevalence of diabetes around the world, clinical trials face significant recruitment challenges brought on by increasing competition for patients, eligibility criteria and stricter regulatory requirements. Well over 200 drugs are currently in development for diabetes and related conditions. Given this level of drug development activity, as many as 500,000 patients are needed to enroll in these trials. To reduce the risk of costly enrollment delays, tailored recruitment strategies need to proactively address protocol challenges, consider patient motivations and complement local recruitment practices.
Missing data may also have costly consequences at the end of a study. Retention of patients has been recently highlighted by regulatory pressures to collect final status on outcomes trials. To reduce the risk of dropout or lost to follow-up, addressing protocol challenges up front may help to mitigate this risk. Retention strategies should be designed to reduce barriers to enrollment, promote protocol compliance and ensure a means of follow up with patients.
The discussion will include ways to develop targeted strategies with the potential to increase enrollment rates and reduce lost to follow-up by:
Copyright©2012 Vocus, Inc.
All rights reserved